Gast ::
| Hauptseite > Publikationsdatenbank > The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma > print |
| Hauptseite > Publikationsdatenbank > The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma > print |
| 001 | 255687 | ||
| 005 | 20220930130047.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/nov088 |2 doi |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a WOS:000361306400015 |2 WOS |
| 024 | 7 | _ | |a altmetric:4057332 |2 altmetric |
| 024 | 7 | _ | |a pmid:26008606 |2 pmid |
| 037 | _ | _ | |a FZJ-2015-05820 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Galldiks, N. |0 P:(DE-Juel1)143792 |b 0 |e Corresponding author |
| 245 | _ | _ | |a The use of dynamic O-(2-18F-fluoroethyl)-L-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma |
| 260 | _ | _ | |a Oxford |c 2015 |b Oxford Univ. Press |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1443094779_332 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 520 | _ | _ | |a Background We evaluated the diagnostic value of static and dynamic O-(2-[18F]fluoroethyl)-l-tyrosine (18F-FET) PET parameters in patients with progressive or recurrent glioma.Methods We retrospectively analyzed 132 dynamic 18F-FET PET and conventional MRI scans of 124 glioma patients (primary World Health Organization grade II, n = 55; grade III, n = 19; grade IV, n = 50; mean age, 52 ± 14 y). Patients had been referred for PET assessment with clinical signs and/or MRI findings suggestive of tumor progression or recurrence based on Response Assessment in Neuro-Oncology criteria. Maximum and mean tumor/brain ratios of 18F-FET uptake were determined (20–40 min post-injection) as well as tracer uptake kinetics (ie, time to peak and patterns of the time–activity curves). Diagnoses were confirmed histologically (95%) or by clinical follow-up (5%). Diagnostic accuracies of PET and MR parameters for the detection of tumor progression or recurrence were evaluated by receiver operating characteristic analyses/chi-square test.Results Tumor progression or recurrence could be diagnosed in 121 of 132 cases (92%). MRI and 18F-FET PET findings were concordant in 84% and discordant in 16%. Compared with the diagnostic accuracy of conventional MRI to diagnose tumor progression or recurrence (85%), a higher accuracy (93%) was achieved by 18F-FET PET when a mean tumor/brain ratio ≥2.0 or time to peak <45 min was present (sensitivity, 93%; specificity, 100%; accuracy, 93%; positive predictive value, 100%; P < .001).Conclusion Static and dynamic 18F-FET PET parameters differentiate progressive or recurrent glioma from treatment-related nonneoplastic changes with higher accuracy than conventional MRI. |
| 536 | _ | _ | |a 573 - Neuroimaging (POF3-573) |0 G:(DE-HGF)POF3-573 |c POF3-573 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Stoffels, G. |0 P:(DE-Juel1)131627 |b 1 |
| 700 | 1 | _ | |a Filss, C. |0 P:(DE-Juel1)141877 |b 2 |
| 700 | 1 | _ | |a Rapp, M. |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Blau, T. |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Tscherpel, C. |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Ceccon, G. |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Dunkl, V. |0 P:(DE-Juel1)156211 |b 7 |
| 700 | 1 | _ | |a Weinzierl, M. |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Stoffel, M. |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Sabel, M. |0 P:(DE-Juel1)165921 |b 10 |
| 700 | 1 | _ | |a Fink, G. R. |0 P:(DE-Juel1)131720 |b 11 |
| 700 | 1 | _ | |a Shah, N. J. |0 P:(DE-Juel1)131794 |b 12 |
| 700 | 1 | _ | |a Langen, K.-J. |0 P:(DE-Juel1)131777 |b 13 |
| 773 | _ | _ | |a 10.1093/neuonc/nov088 |g p. nov088 |0 PERI:(DE-600)2094060-9 |n 9 |p 1293-1300 |t Neuro-Oncology |v 17 |y 2015 |x 1523-5866 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.gif?subformat=icon |x icon |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.jpg?subformat=icon-1440 |x icon-1440 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.jpg?subformat=icon-180 |x icon-180 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.jpg?subformat=icon-640 |x icon-640 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/255687/files/Neuro%20Oncol-2015-Galldiks-1293-300.pdf?subformat=pdfa |x pdfa |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:255687 |p VDB |p OpenAPC |p openCost |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)143792 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)131627 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)141877 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 11 |6 P:(DE-Juel1)131720 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 12 |6 P:(DE-Juel1)131794 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 13 |6 P:(DE-Juel1)131777 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-573 |2 G:(DE-HGF)POF3-500 |v Neuroimaging |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
| 914 | 1 | _ | |y 2015 |
| 915 | _ | _ | |a Allianz-Lizenz / DFG |0 StatID:(DE-HGF)0400 |2 StatID |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2014 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b NEURO-ONCOLOGY : 2014 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-3-20090406 |k INM-3 |l Kognitive Neurowissenschaften |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-4-20090406 |k INM-4 |l Physik der Medizinischen Bildgebung |x 1 |
| 920 | 1 | _ | |0 I:(DE-82)080010_20140620 |k JARA-BRAIN |l JARA-BRAIN |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-3-20090406 |
| 980 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| 980 | _ | _ | |a I:(DE-82)080010_20140620 |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a APC |
| 981 | _ | _ | |a I:(DE-Juel1)INM-4-20090406 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|